Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases)

Frontiers in Immunology

Volumn 5, Issue NOV, 2014, Pages

  Gremese, Elisa ^a   Tolusso, Barbara ^a   Gigante, Maria Rita ^a   Ferraccioli, Gianfranco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Adipokines; Body mass index; Inflammation; Obesity; Rheumatic diseases; Rheumatoid arthritis

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; B7 ANTIGEN; CERTOLIZUMAB PEGOL; CHEMERIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIGMENT EPITHELIUM DERIVED FACTOR; RESISTIN; SIRTUIN 1; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ADIPOSE TISSUE; ARTHRITIS; BARE LYMPHOCYTE SYNDROME; BODY MASS; CARDIOVASCULAR RISK; DISEASE SEVERITY; HUMAN; INSULIN RESISTANCE; LUPUS ERYTHEMATOSUS NEPHRITIS; META ANALYSIS (TOPIC); METABOLISM; MORBIDITY; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS DISEASE ACTIVITY INDEX; RISK ASSESSMENT; SJOEGREN SYNDROME; SPONDYLARTHRITIS; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; WAIST CIRCUMFERENCE;

EID: 84919351846     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00576     Document Type: Review

References (128)

1. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet (2011) 378:804-14. doi: 10.1016/S0140-6736(11)60813-1
2. Hauner H. Secretory factors from human adipose tissue and their functional role. Proc Nutr Soc (2005) 64:163-9. doi:10.1079/PNS2005428
3. van der Meer JW, Netea MG. A salty taste to autoimmunity. N Engl J Med (2013) 368:2520-1. doi:10.1056/NEJMcibr1303292
4. World Health Organization. Health Topics: Obesity. Geneva: World Health Organization (2011). Available from: http://www.who.int/topics/obesity/en/
5. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. Obes Res (1998) 6:51S-209S.
6. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation (2004) 109:433-8. doi:10.1161/01.CIR.0000111245.75752.C6
7. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Nevill AM, Douglas KM, Jamurtas A, et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis (2007) 66:1316-21. doi:10.1136/ard.2006.060319
8. Katz PP, Yazdany J, Trupin L, Schmajuk G, Margaretten M, Barton J, et al. Sex differences in assessment of obesity in rheumatoid arthritis. Arthritis Care Res (2013) 65:62-70. doi:10.1002/acr.21810
9. Keys A, Fidanza F, Karvonen MJ, Kimura N, Taylor HL. Indices of relative weight and obesity. Int J Epidemiol (2014) 43:655-65. doi:10.1093/ije/dyu058
10. De Luca G, Gremese E, Messuti L, Bosello SL, Fedele AL, Gigante MR, et al. Distribution of body mass index and metabolic syndrome in patients with inflammatory autoimmune diseases from a single Italian centre. Ann Rheum Dis (2013) 72:744. doi:10.1136/annrheumdis-2013-eular.1060
11. Schipper HS, Prakken B, Kalkhoven E, Boes M. Adipose tissue-resident immune cells: key players in immunometabolism. Trends Endocrinol Metab (2012) 23:407-15. doi:10.1016/j.tem.2012.05.011
12. Cildir G, Akincilar SC, Tergaonkar V. Chronic adipose tissue inflammation: all immune cells on the stage. Trends Mol Med (2013) 19:487-500. doi:10.1016/j.molmed.2013.05.001
13. Lumeng CN, DelProposto JB, Westcott DJ, Saltiel AR. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes (2008) 57:3239-46. doi:10.2337/db08-0872
14. Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord (2003) 27(Suppl 3):S49-52. doi:10.1038/sj.ijo.0802501
15. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science (2001) 293:1673-7. doi:10.1126/science.1061620
16. Solinas G, Vilcu C, Neels JG, Bandyopadhyay GK, Luo JL, Naugler W, et al. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab (2007) 6:386-97. doi:10.1016/j.cmet.2007.09.011
17. Deng T, Lyon CJ, Minze LJ, Lin J, Zou J, Liu JZ, et al. Class II major histocompatibility complex plays an essential role in obesity-induced adipose inflammation. Cell Metab (2013) 17:411-22. doi:10.1016/j.cmet.2013.02.009
18. Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med (2012) 18:363-74. doi:10.1038/nm.2627
19. Jhun JY, Yoon BY, Park MK, Oh HJ, Byun JK, Lee SY, et al. Obesity aggravates the joint inflammation in a collagen-induced arthritis model through deviation to Th17 differentiation. Exp Mol Med (2012) 44:424-31. doi:10.3858/emm.2012.44.7.047
20. Muller-Ladner U, Neumann E. Rheumatoid arthritis: the multifaceted role of adiponectin in inflammatory joint disease. Nat Rev Rheumatol (2009) 5:659-60. doi:10.1038/nrrheum.2009.232
21. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Kitas GD. Obesity in rheumatoid arthritis. Rheumatology (2011) 50:450-62. doi:10.1093/rheumatology/keq266
22. Gómez R, Conde J, Scotece M, Gómez-Reino JJ, Lago F, Gualillo O. What's new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol (2011) 7:528-36. doi:10.1038/nrrheum.2011.107
23. Abella V, Scotece M, Conde J, López V, Lazzaro V, Pino J, et al. Adipokines, metabolic syndrome and rheumatic diseases. J Immunol Res (2014) 2014:343746. doi:10.1155/2014/343746
24. Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul (2009) 43:157-68.
25. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev (2005) 26:439-51. doi:10.1210/er.2005-0005
26. Frommer KW, Zimmermann B, Meier FM, Schröder D, Heil M, Schäffler A, et al. Adiponectin-mediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis. Arthritis Rheum (2010) 62:2886-99. doi:10.1002/art.27616
27. Jéquier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci (2002) 967:379-88. doi:10.1111/j.1749-6632.2002.tb04293.x
28. Otero M, Lago R, Lago F, Casanueva FF, Dieguez C, Gómez-Reino JJ, et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett (2005) 579:295-301. doi:10.1016/j.febslet.2004.11.024
29. Otero M, Lago R, Gomez R, Dieguez C, Lago F, Gómez-Reino J, et al. Towards a proinflammatory and immunomodulatory emerging role of leptin. Rheumatology (2006) 45:944-50. doi:10.1093/rheumatology/kel157
30. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature (1998) 394:897-901. doi:10.1038/29795
31. Del Prete A, Salvi V, Sozzani S. Adipokines as potential biomarkers in rheumatoid arthritis. Mediators Inflamm (2014) 2014:425068. doi:10.1155/2014/425068
32. Rho YH, Solus J, Sokka T, Oeser A, Chung CP, Gebretsadik T, et al. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum (2009) 60:1906-14. doi:10.1002/art.24626
33. Otvos L Jr, Shao WH, Vanniasinghe AS, Amon MA, Holub MC, Kovalszky I, et al. Toward understanding the role of leptin and leptin receptor antagonism in preclinical models of rheumatoid arthritis. Peptides (2011) 32:1567-74. doi:10.1016/j.peptides.2011.06.015
34. Heilbronn LK, Rood J, Janderova L, Albu JB, Kelley DE, Ravussin E, et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab (2004) 89:1844-8. doi:10.1210/jc.2003-031410
35. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes (2001) 50:2199-202. doi:10.2337/diabetes.50.10.2199
36. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol (2005) 174:5789-95. doi:10.4049/jimmunol.174.9.5789
37. Senolt L, Housa D, Vernerová Z, Jirásek T, Svobodová R, Veigl D, et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis (2007) 66:458-63. doi:10.1136/ard.2006.054734
38. Sethi JK, Vidal-Puig A. Visfatin: the missing linkbetween intra-abdominal obesity and diabetes? Trends Mol Med (2005) 11:344-7. doi:10.1016/j.molmed.2005.06.010
39. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab (2006) 91:1578-81. doi:10.1210/jc.2005-2248
40. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol (2007) 178:1748-58. doi:10.4049/jimmunol.178.3.1748
41. Evans L, Williams AS, Hayes AJ, Jones SA, Nowell M. Suppression of leukocyte infiltration and cartilage degradation by selective inhibition of pre-B cell colony-enhancing factor/visfatin/nicotinamide phosphoribosyltransferase: Apo866-mediated therapy in human fibroblasts and murine collagen-induced arthritis. Arthritis Rheum (2011) 63:1866-77. doi:10.1002/art.30338
42. Steele FR, Chader GJ, Johnson LV, Tombran-Tink J. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci U S A (1993) 90:1526-30. doi:10.1073/pnas.90.4.1526
43. Becerra SP, Sagasti A, Spinella P, Notario V. Pigment epithelium-derived factor behaves like a noninhibitory serpin. Neurotrophic activity does not require the serpin reactive loop. J Biol Chem (1995) 270:25992-9. doi:10.1074/jbc.270.43.25992
44. Tombran-Tink J, Chader GG, Johnson LV. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res (1991) 53:411-4. doi:10.1016/0014-4835(91)90248-D
45. Fernandez-Garcia NI, Volpert OV, Jimenez B. Pigment epithelium-derived factor as a multifunctional antitumor factor. J Mol Med (2007) 85:15-22. doi:10.1007/s00109-006-0111-z
46. Crowe S, Wu LE, Economou C, Turpin SM, Matzaris M, Hoehn KL, et al. Pigment epithelium-derived factor contributes to insulin resistance in obesity. Cell Metab (2009) 10:40-7. doi:10.1016/j.cmet.2009.06.001
47. Filleur S, Nelius T, de Riese W, Kennedy RC. Characterization of PEDF: a multi-functional serpin family protein. J Cell Biochem (2009) 106:769-75. doi:10.1002/jcb.22072
48. Famulla S, Lamers D, Hartwig S, Passlack W, Horrighs A, Cramer A, et al. Pigment epithelium-derived factor (PEDF) is one of the most abundant proteins secreted by human adipocytes and induces insulin resistance and inflammatory signaling in muscle and fat cells. Int J Obes (2011) 35:762-72. doi:10.1038/ijo.2010.212
49. Matsumoto K, Ishikawa H, Nishimura D, Hamasaki K, Nakao K, Eguchi K. Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma. Hepatology (2004) 40:252-9. doi:10.1002/hep.20259
50. Zvonic S, Lefevre M, Kilroy G, Floyd ZE, DeLany JP, Kheterpal I, et al. Secretome of primary cultures of human adipose-derived stem cells: modulation of serpins by adipogenesis. Mol Cell Proteomics (2007) 6:18-28. doi:10.1074/mcp.M600217-MCP200
51. Sabater M, Moreno-Navarrete JM, Ortega FJ, Pardo G, Salvador J, Ricart W, et al. Circulating pigment epithelium-derived factor levels are associated with insulin resistance and decrease after weight loss. Clin Endocrinol Metab (2010) 95:4720-8. doi:10.1210/jc.2010-0630
52. Chiellini C, Cochet O, Negroni L, Samson M, Poggi M, Ailhaud G, et al. Characterization of human mesenchymal stem cell secretome at early steps of adipocyte and osteoblast differentiation. BMC Mol Biol (2008) 9:26. doi:10.1186/1471-2199-9-26
53. Yamagishi S, Adachi H, Abe A, Yashiro T, Enomoto M, Furuki K, et al. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab (2006) 91:2447-50. doi:10.1210/jc.2005-2654
54. Wang P, Smit E, Brouwers MC, Goossens GH, van der Kallen CJ, van Greevenbroek MM, et al. Plasma pigment epithelium-derived factor is positively associated with obesity in Caucasian subjects, in particular with the visceral fat depot. Eur J Endocrinol (2008) 159:713-8. doi:10.1530/EJE-08-0521
55. Jenkins A, Zhang SX, Gosmanova A, Aston C, Dashti A, Baker MZ, et al. Increased serum pigment epithelium derived factor levels in type 2 diabetes patients. Diabetes Res Clin Pract (2008) 82:e5-7. doi:10.1016/j.diabres.2008.06.019
56. Lange J, Yafai Y, Reichenbech A, Wiedemann P, Eichler W. Regulation of epithelium-derived factor production and release by retinal glial (Muller) cells under hypoxia. Invest Ophthalmol Vis Sci (2008) 49:5161-7. doi:10.1167/iovs.08-2201
57. Chavan SS, Hudson LK, Li JH, Ochani M, Harris Y, Patel NB, et al. Identification of pigment epithelium-derived factor as an adipocyte-derived inflammatory factor. Mol Med (2012) 18:1161-8. doi:10.2119/molmed.2012.00156
58. Yoshizaki T, Schenk S, Imamura T, Babendure JL, Sonoda N, Bae EJ, et al. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am J Physiol Endocrinol Metab (2010) 298:E419-28. doi:10.1152/ajpendo.00417.2009
59. Gillum MP, Kotas ME, Erion DM, Kursawe R, Chatterjee P, Nead KT, et al. SirT1 regulates adipose tissue inflammation. Diabetes (2011) 60:3235-45. doi:10.2337/db11-0616
60. Voigt LF, Koepsell TD, Nelson JL, Dugowson CE, Daling JR. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology (1994) 5:525-32.
61. Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, Scott DG, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum (1997) 40:1955-61. doi:10.1002/art.1780401106
62. Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum (2011) 63:359-64. doi:10.1002/art.30136
63. Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B, Giardina AR, et al. Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to personalized medicine. Arthritis Care Res (2013) 65:94-100. doi:10.1002/acr.21768
64. Ottaviani S, Allanore Y, Tubach F, Forien M, Gardette A, Pasquet B, et al. Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther (2012) 14:R115. doi:10.1186/ar3841
65. Gremese E, Tolusso B, Fedele AL, Gigante MR, Carbonella A, Canestri S, et al. Metaflammation, PEDF and chemerin: potential systemic factors which link obesity to response to therapy in early rheumatoid arthritis. Ann Rheum Dis (2014) 73(Suppl 2). doi:10.1136/annrheumdis-2014-eular.4936
66. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology (2007) 148:4687-94. doi:10.1210/en.2007-0175
67. Sell H, Divoux A, Poitou C, Basdevant A, Bouillot JL, Bedossa P, et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab (2010) 95:2892-6. doi:10.1210/jc.2009-2374
68. Eisinger K, Bauer S, Schäffler A, Walter R, Neumann E, Buechler C, et al. Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis. Exp Mol Pathol (2012) 92:90-6. doi:10.1016/j.yexmp.2011.10.006
69. Kaneko K, Miyabe Y, Takayasu A, Fukuda S, Miyabe C, Ebisawa M, et al. Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis. Arthritis Res Ther (2011) 13:R158. doi:10.1186/ar3475
70. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest (2008) 118:3537-45. doi:10.1172/JCI36389
71. Kishimoto T. Interleukin-6: from basic science to medicine: 40 years in immunology. Annu Rev Immunol (2005) 23:1-21. doi:10.1146/annurev.immunol.23.021704.115806
72. Iwamoto T, Okamoto H, Toyama Y, Momohara S. Molecular aspects of rheumatoid arthritis: chemokines in the joints of patients. FEBS J (2008) 275:4448-55. doi:10.1111/j.1742-4658.2008.06580.x
73. Ha YJ, Kang EJ, Song JS, Park YB, Lee SK, Choi ST. Plasma chemerin levels in rheumatoid arthritis are correlated with disease activity rather than obesity. Joint Bone Spine (2014) 81:189-90. doi:10.1016/j.jbspin.2013.07.013
74. Naranjo A, Sokka T, Descalzo MA, Calvo-Alén J, Hørslev-Petersen K, Luukkainen RK, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther (2008) 10:R30. doi:10.1186/ar2383
75. Armstrong DJ, McCausland EM, Quinn AD, Wright GD. Obesity and cardiovascular risk factors in rheumatoid arthritis. Rheumatology (2006) 45:782. doi:10.1093/rheumatology/kel124
76. Hernandez Avila M, Liang MH, Willett WC, Stampfer MJ, Colditz GA, Rosner B, et al. Reproductive factors, smoking, and the risk for rheumatoid arthritis. Epidemiology (1990) 1:285-91. doi:10.1097/00001648-199007000-00005
77. Cerhan JR, Saag KG, Criswell LA, Merlino LA, Mikuls TR. Blood transfusion, alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women. J Rheumatol (2002) 29:246-54.
78. Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfahrt J, et al. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther (2006) 8:R133. doi:10.1186/ar2022
79. Crowson CS, Matteson EL, Davis JM III, Gabriel SE. Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res (2013) 65:71-7. doi:10.1002/acr.21660
80. Wesley A, Bengtsson C, Elkan AC, Klareskog L, Alfredsson L, Wedrén S, et al. Association between body mass index and anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis: results from a population-based case-control study. Arthritis Care Res (Hoboken) (2013) 65:107-12. doi:10.1002/acr.21749
81. Lahiri M, Luben RN, Morgan C, Bunn DK, Marshall T, Lunt M, et al. Using lifestyle factors to identify individuals at higher risk of inflammatory polyarthritis (results from the European Prospective Investigation of Cancer-Norfolk and the Norfolk Arthritis Register - the EPIC-2-NOAR Study). Ann Rheum Dis (2014) 73:219-26. doi:10.1136/annrheumdis-2012-202481
82. Lu B, Hiraki LT, Sparks JA, Malspeis S, Chen CY, Awosogba JA, et al. Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study. Ann Rheum Dis (2014) 3(11):1914-22. doi:10.1136/annrheumdis-2014-205459
83. Ajeganova S, Andersson ML, Hafström I; BARFOT Study Group. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res (2013) 65:78-87. doi:10.1002/acr.21710
84. Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, Nevill AM, Jamurtas AZ, Koutedakis Y, et al. Underweight and obese states both associate with worse disease activity and physical function in patients with established rheumatoid arthritis. Clin Rheumatol (2009) 28:439-44. doi:10.1007/s10067-008-1073-z
85. Jawaheer D, Olsen J, Lahiff M, Forsberg S, Lahteenmaki J, da Silveira IG, et al. Gender, body mass index and rheumatoid arthritis disease activity: results from the QUEST-RA study. Clin Exp Rheumatol (2010) 28:454-61. doi:10.1002/acr.21978
86. Heimans L, van den Broek M, le Cessie S, Siegerink B, Riyazi N, Han KH, et al. Association of high body mass index with decreased treatment response to combination therapy in recent-onset rheumatoid arthritis patients. Arthritis Care Res (2013) 65:1235-42. doi:10.1002/acr.21978
87. Gremese E, Fedele AL, Gigante MR, Tolusso B, Carbonella A, Bosello SL, et al. The body mass index: a determinant of remission in early rheumatoid arthritis. Ann Rheum Dis (2013) 72:A113. doi:10.1136/annrheumdis-2013-eular.383
88. Visser M, Langlois J, Guralnik JM, Cauley JA, Kronmal RA, Robbins J, et al. High body fatness, but not low fat-free mass, predicts disability in older men and women: the Cardiovascular Health Study. Am J Clin Nutr (1998) 68:584-90.
89. Hassan MK, Joshi AV, Madhavan SS, Amonkar MM. Obesity and health-related quality of life: a cross-sectional analysis of the US population. Int J Obes Relat Metab Disord (2003) 27:1227-32. doi:10.1038/sj.ijo.0802396
90. Caplan L, Davis LA, Bright CM, Kerr GS, Lazaro DM, Khan NA, et al. Body mass index and the rheumatoid arthritis swollen joint count: an observational study. Arthritis Care Res (2013) 65:101-6. doi:10.1002/acr.21734
91. Westhoff G, Rau R, Zink A. Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum (2007) 56:3575-82. doi:10.1002/art.23033
92. van der Helm-van Mil AH, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis (2008) 67:769-74. doi:10.1136/ard.2007.078832
93. Kaufmann J, Kielstein V, Kilian S, Stein G, Hein G. Relation between body mass index and radiological progression in patients with rheumatoid arthritis. J Rheumatol (2003) 30:2350-5.
94. Baker JF, Ostergaard M, George M, Shults J, Emery P, Baker DG, et al. Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1-2 years. Ann Rheum Dis (2014) 73(11):1923-8. doi:10.1136/annrheumdis-2014-205544
95. Giles JT, Allison M, Bingham CO III, Scott WM Jr, Bathon JM. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum (2009) 61:1248-56. doi:10.1002/art.24789
96. Ferraccioli G, Trotta F, Punzi L, Ferri C, Sarzi-Puttini P, Bambara LM, et al. Body weight and response to biologics in RA and spondyloarthritides. Obesity reduces the rate of remission-response. The GISEA registry. Arthritis Rheum (2010) 62(Suppl 10):297.
97. Smolen JS, Szumski S, Koening AS, Jones TV. Impact of body mass index on response to etanercept therapy in subjects with moderately active rheumatoid arthritis in the PRESERVE trial. Arthritis Rheum (2011) 63(Suppl):S154.
98. Sandberg ME, Bengtsson C, Källberg H, Wesley A, Klareskog L, Alfredsson L, et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis (2014) 73(11):2029-33. doi:10.1136/annrheumdis-2013-205094
99. Gremese E, Ferraccioli G. The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev (2011) 10:582-9. doi:10.1016/j.autrev.2011.04.018
100. Wojtal KA, Rogler G, Scharl M, Biedermann L, Frei P, Fried M, et al. Fc gamma receptor CD64 modulates the inhibitory activity of infliximab. PLoS One (2012) 7:e43361. doi:10.1371/journal.pone.0043361
101. Palming J, Gabrielsson BG, Jennische E, Smith U, Carlsson B, Carlsson LM, et al. Plasma cells and Fc receptors in human adipose tissue-lipogenic and anti-inflammatory effects of immunoglobulins on adipocytes. Biochem Biophys Res Commun (2006) 343:43-8. doi:10.1016/j.bbrc.2006.02.114
102. Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A, et al. Body weight, gender and response to TNF-a blockers in axial spondyloarthritis. Rheumatology (2014) 53:875-81. doi:10.1093/rheumatology/ket433
103. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes (2012) 2:e54. doi:10.1097/HJH.0b013e32835bcce1
104. Bhole VM, Choi HK, Burns LC, Vera Kellet C, Lacaille DV, Gladman DD, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (2012) 51:552-6. doi:10.1093/rheumatology/ker349
105. Love TJ, Zhu Y, Zhang Y, Wall-Burns L, Ogdie A, Gelfand JM, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis (2012) 71:1273-7. doi:10.1136/annrheumdis-2012-201299
106. Di Minno MN, Peluso R, Iervolino S, Lupoli R, Russolillo A, Scarpa R, et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (2013) 65:141-7. doi:10.1002/acr.21711
107. Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis (2014). doi:10.1136/annrheumdis-2013-204448
108. Naldi L, Conti A, Cazzaniga S, Patrizi A, Pazzaglia M, Lanzoni A, et al. Diet and physical exercise in psoriasis: a randomized controlled trial. Br J Dermatol (2014) 170:634-42. doi:10.1111/bjd.12735
109. Di Minno MN, Peluso R, Iervolino S, Russolillo A, Lupoli R, Scarpa R, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor a blockers. Ann Rheum Dis (2014) 73:1157-62. doi:10.1136/annrheumdis-2012-202812
110. Jensen P, Zachariae C, Christensen R, Geiker NR, Schaadt BK, Stender S, et al. Effect of weight loss on the cardiovascular risk profile of obese patients with psoriasis. Acta Derm Venereol (2014) 94(6):691-4. doi:10.2340/00015555-1824
111. Katz P, Gregorich S, Yazdany J, Trupin L, Julian L, Yelin E, et al. Obesity and its measurement in a community-based sample of women with systemic lupus erythematosus. Arthritis Care Res (2011) 63:261-8. doi:10.1002/acr.20343
112. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins lupus cohort. Lupus (2000) 9:170-5. doi:10.1191/096120300678828226
113. Oeser A, Chung CP, Asanuma Y, Avalos I, Stein CM. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum (2005) 52:3651-9. doi:10.1002/art.21400
114. Chaiamnuay S, Bertoli AM, Fernandez M; LUMINA Study Group. The impact of increased body mass index on systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA XLVI). J Clin Rheumatol (2007) 13:128-33. doi:10.1097/RHU.0b013e3180645865
115. Karadag O, Calguneri M, Atalar E, Yavuz B, Akdogan A, Kalyoncu U, et al. Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. Clin Rheumatol (2007) 26:695-9. doi:10.1007/s10067-006-0376-1
116. Lozovoy MA, Simão AN, Hohmann MS, Simão TN, Barbosa DS, Morimoto HK, et al. Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome. Lupus (2011) 20:1356-64. doi:10.1177/0961203311411348
117. Almehed K, Carlsten H, Forsblad-d'Elia H. Health-related quality of life in systemic lupus erythematosus and its association with disease and work disability. Scand J Rheumatol (2010) 39:58-62. doi:10.3109/03009740903124408
118. Rizk A, Gheita TA, Nassef S, Abdallah A. The impact of obesity in systemic lupus erythematosus on disease parameters, quality of life, functional capacity and the risk of atherosclerosis. Int J Rheum Dis (2012) 15:261-7. doi:10.1111/j.1756-185X.2011.01698.x
119. Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum (2005) 52:2774-82. doi:10.1002/art.21224
120. Chaiamnuay S, Bertoli AM, Roseman JM, McGwin G, Apte M, Durán S, et al. African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV). Ann Rheum Dis (2007) 66:618-22. doi:10.1136/ard.2006.059311
121. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (2003) 82:299-308. doi:10.1097/01.md.0000091181.93122.55
122. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med (1976) 60:221-5. doi:10.1016/0002-9343(76)90431-9
123. Ngian GS, Sahhar J, Proudman SM, Stevens W, Wicks IP, Van Doornum S. Prevalence of coronary heart disease and cardiovascular risk factors in a national cross-sectional cohort study of systemic sclerosis. Ann Rheum Dis (2012) 71:1980-3. doi:10.1136/annrheumdis-2011-201176
124. Caramaschi P, Biasi D, Caimmi C, Barausse G, Gatti D, Ferrari M, et al. Relationship between body composition and both cardiovascular risk factors and lung function in systemic sclerosis. Clin Rheumatol (2014) 33:77-82. doi:10.1007/s10067-013-2388-y
125. Rossi AP, Watson NL, Newman AB, Harris TB, Kritchevsky SB, Bauer DC, et al. Effects of body composition and adipose tissue distribution on respiratory function in elderly men and women: the health, aging, and body composition study. J Gerontol A Biol Sci Med Sci (2011) 66:801-8. doi:10.1093/gerona/glr058
126. Marighela TF, Genaro Pde S, Pinheiro MM, Szejnfeld VL, Kayser C. Risk factors for body composition abnormalities in systemic sclerosis. Clin Rheumatol (2013) 32:1037-44. doi:10.1007/s10067-013-2235-1
127. Assassi S, Del Junco D, Sutter K, McNearney TA, Reveille JD, Karnavas A, et al. Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum (2009) 61:1403-11. doi:10.1002/art.24734
128. Lendrem D, Mitchell S, McMeekin P, Bowman S, Price E, Pease CT, et al. Health-related utility values of patients with primary Sjögren's syndrome and its predictors. Ann Rheum Dis (2014) 73:1362-8. doi:10.1136/annrheumdis-2012-202863